focus -WSS

focus

author：knowledge 2025-09-14 18:32:32 - browse：89

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： 5 wounded, 2 critically, in Michigan shopping center shooting

WSS

After sickle

FDA approves world's first CRISPR

Radiology is caught between AI's potential and concern for patients

STAT letters to the editor on burnt

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

explore

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

United colonoscopy coverage change 'may cost lives,' doctors say

Many immigrants are left out of maternal health programs

The high cost of giving birth even with insurance

Roche to buy Carmot Therapeutics, developer of obesity drugs

Medical records are filled with copy

Leukemia patients are helped by Syndax's new type of therapy

Hollywood unions extend contract negotiations for actors

HCA says smaller share of spending going to labor

focus

5 wounded, 2 critically, in Michigan shopping center shooting

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

FDA approves world's first CRISPR

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

The woman behind the Dana Farber

knowledge

focus

hotspot

hotspot